Reck M, Rodríguez-Abreu D, Robinson AG, et al.; KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-1833.
DOI: 10.1056/NEJMoa1606774
Reck M, Rodriguez-Aberu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab Versus platinum-based chemotherapy for advanced Non-small cell lung cancer With PD-L1 tumor proportion score of 50 % or greater. J Clin Oncol 2019;37:537-546.
DOI: 10.1200/JCO.18.00149
Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1 %: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018;36 (suppl; abstr LBA4).
DOI: 10.1200/JCO.2018.36.18_suppl.LBA4
Carbone DP, Reck M, Paz-Ares L, et al.; CheckMate 026 Investigators. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;376:2415-2426.
DOI: 10.1056/NEJMoa1613493
Paz-Ares L, Luft A, Vicente D, et al.; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:2040-2051.
DOI: 10.1056/NEJMoa1810865
Socinski MA, Koynov KD, Berard H, et al. IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs. carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. Ann Oncol 2018;29(suppl 8).
DOI: 10.1093/annonc/mdy424.077
Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:198-211. Erratum in: Lancet Oncol 2021 Mar;22(3):e92.
DOI: 10.1016/S1470-2045(20)30641-0
Cobo M, Carbone DP, Ciuleanu TE, et al. First-line nivolumab + ipilimumab + chemotherapy vs chemotherapy alone in patients with metastatic non-small cell lung cancer from CheckMate 9LA: 4-year clinical update including subgroup analyses by tumor histology and PD-L1 level. Presented at the Grupo Español de Cáncer de Pulmón (GECP) 15th Congress on Lung Cancer; November 23-24, 2023; Madrid, Spain.
Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35:3924-3933.
DOI: 10.1200/JCO.2017.74.3062
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-1550.
DOI: 10.1016/S0140-6736(15)01281-7
Fehrenbacher L, Spira A, Ballinger M, et al.; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-1846.
DOI: 10.1016/S0140-6736(16)00587-0
Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-673.
DOI: 10.1016/S0140-6736(14)60845-X
Garassino MC, Martelli O, Broggini M, et al; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981-988.
DOI: 10.1016/S1470-2045(13)70310-3
Soria JC, Felip E, Cobo M, et al.; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015;16:897-907.
DOI: 10.1016/S1470-2045(15)00006-6
Goss GD, Felip E, Cobo M, et al. Association of ERBB mutations with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell carcinoma: secondary analysis of the LUX-Lung 8 randomized clinical trial. JAMA Oncol 2018;4:1189-1197.
DOI: 10.1001/jamaoncol.2018.0775
Leong Swan Swan, Chee Keong Toh, Wan Teck Lim, et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2007;2:230-236.
DOI: 10.1097/JTO.0b013e318031d06f
Sandler Alan, Ettinger David. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. The Oncologist 1999;4:241-251.
DOI: 10.1634/theoncologist.4-3-241
Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non--small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-1613.
DOI: 10.1200/JCO.1989.7.11.1602
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers [published correction appears in Nature 2012;491:288]. Nature 2012;489:519-525.
Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014;32:121-128.
DOI: 10.1200/JCO.2013.50.8556
Paik PK, Shen R, Won H, et al. Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov 2015;5:610-621.
DOI: 10.1158/2159-8290.CD-14-1129
Redman, M.W., Papadimitrakopoulou, V.A., Minichiello, K., et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet. Oncol 2020;21:1589-1601.
Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., et al. Erlotinib in previously treated non–small-cell lung cancer. N. Engl. J. Med 2005;353:123-132.
Heist, R.S., Sequist, L.V., and Engelman, J.A. Genetic changes in squamous cell lung cancer: a review. J. Thorac. Oncol 2012;7:924-933.
Socinski, M.A., Obasaju, C., Gandara, et al. Current and emergent therapy options for advanced squamous cell lung cancer.J. Thorac. Oncol 2018;13:165-183.
Pirker, R., Pereira, J.R., Szczesna, A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-1531.
DOI: 10.1016/S0140-6736(09)60569-9
Thatcher, N., Hirsch, F.R., Luft, A.V, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as firstline therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet. Oncol 2015;16:763-774.
Desai, A., and Adjei, A.A. FGFR signaling as a target for lung cancer therapy. J. Thorac. Oncol 2016;11:9-20.
Hashemi-Sadraei, N., and Hanna, N. Targeting FGFR in squamous cell carcinoma of the lung. Target Oncol 2017;12,741-755.
DOI: 10.1007/s11523-017-0513-6
Tsironis, G., Ziogas, D.C., Kyriazoglou, et al. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann. Transl. Med 2018;6:143.
Weiss, J., Sos, M.L., Seidel, D., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med 2010; 2, 62ra93.
DOI: 10.1126/scitranslmed.3001451
Reck, M., Kaiser, R., Mellemgaard, A., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet. Oncol 2014;15,143-155.
DOI: 10.1016/S1470-2045(13)70586-2
Hanna, N.H., Kaiser, R., Sullivan, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double blind, phase III trial. Lung Cancer 2016;102,65-73.
DOI: 10.1016/j.lungcan.2016.10.011
Lim, S.H., Sun, J.M., Choi, Y.L., et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: a single-arm, phase 2 study. Cancer 2016;122,3024-3031
DOI: 10.1002/cncr.30135
Qin, A., Johnson, A., Ross, et al. Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J. Thorac. Oncol 2019;14:54-62.
Hammerman, P.S., Sos, M.L., Ramos, A.H., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1,78-89.
Payne, L.S., and Huang, P.H. Discoidin domain receptor 2 signaling networks and therapy in lung cancer. J. Thorac. Oncol 2014;9:900-904.
Ricordel, C., Lespagnol, A., Llamas-Gutierrez, F., et al. Mutational landscape of DDR2 gene in lung squamous cell carcinoma using next-generation sequencing. Clin. Lung Cancer 2018;19:163-169.e4.
DOI: 10.1016/j.cllc.2017.10.006
Dotto, G.P., and Rustgi, A.K. (2016). Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell 2016;29, 622–637.
DOI: 10.1016/j.ccell.2016.04.004
Kerr, K.M., Dafni, U., Schulze, K., et al. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Ann. Oncol 2018;29:200-208.
Heist, R.S., Sequist, L.V., and Engelman, J.A. Genetic changes in squamous cell lung cancer: a review. J. Thorac. Oncol 2012;7:924–933.
Weeden, C.E., Chen, Y., Ma, S.B., et al. Lung basal stem cells rapidly repair DNA damage using the error-prone nonhomologous end-joining pathway. PLoS Biol 2017;15, e2000731.
DOI: 10.1371/journal.pbio.2000731
Satpathy, S., Krug, K., Jean Beltran, P.M., et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell 2021:184, 4348-4371.e40.
Ahn, E.R., Mangat, P.K., Garrett-Mayer, E., et al. Palbociclib in patients with non–small-cell lung cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. JCO Precis.
Oncol 2020;4:757-766.
Patnaik, A., Rosen, L.S., Tolaney, S.M., et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors. Cancer Discov 2016;6;740-753
DOI: 10.1158/2159-8290.CD-16-0095
Edelman, M.J., Redman, M.W., Albain, K.S., et al. SWOG S1400C (NCT02154490)-A phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (Lung-MAP substudy). J. Thorac. Oncol 2019,14.1853–1859.
DOI: 10.1016/j.jtho.2019.06.027
Flavahan, W.A., Gaskell, E., and Bernstein, B.E. Epigenetic plasticityband the hallmarks of cancer. Science 2017;357, eaal2380.
DOI: 10.1126/science.aal2380
Morel, D., Jeffery, D., Aspeslagh, S., et al. Combining epigenetic drugs with other therapies for solid tumours-past lessons and future promise. Nat. Rev. Clin. Oncol 2020;17:91-107.
Drilon, A., Rekhtman, N., Ladanyi, M., and Paik, P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012,13:e418–e426.
DOI: 10.1016/S1470-2045(12)70291-7
Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med 2015;373:1627-1639.
Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015). Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med 2015;373:123-135.
Socinski, M.A., Obasaju, C., Gandara, D., et al. Current and emergent therapy options for advanced squamous cell lung cancer. J. Thorac. Oncol 2018;13.165-183.
DOI: 10.1016/j.jtho.2017.11.111
Wiesweg, M., Mairinger, F., Reis, H., et al. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. Eur. J. Cancer 2020;140:76–85.
Wilkerson, M.D., Yin, X., Hoadley, K.A., et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin. Cancer Res 2010;16:4864-4875.
Número de descargas:
2918
Número de visitas:
291
Citas:
0
